Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cretostimogene in BCG-unresponsive high-risk NMIBC
NCT07283835Phase 2Recruiting
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of cretostimogene grenadenorepvec in non-muscle-invasive bladder cancer (NMIBC), sponsored by Lepu Biopharma Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
cretostimogene grenadenorepvec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07283835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283835.